Presentations / Publications
TOP＞Presentations / Publications
| Classification | Title | Presentations / Publications | News |
| Presentation | Advanced case report of approval for regenerative medical products | 6th Global Quality Assurance Conference, Sendai 2020.2.17-20 |
|
| Presentation | A novel approach to CNS dysfunction of Pompe disease with a fusion protein consisting of anti-transferrin receptor antibody and GAA enzyme | 16th Annual WORLDSymposium™ 2020, Florida, USA 2020.2.10-13 |
（2020.2.3） （2020.2.13） |
| Presentation | Results from a phase 2 trial of a blood-brain barrier penetrating enzyme (JR-141) in patients with MPS II in Brazil | 16th Annual WORLDSymposium™ 2020, Florida, USA 2020.2.10-13 |
（2020.2.3） （2020.2.13） |
| Presentation | Therapy for mucopolysaccharidosis II with an intravenous blood-brain barrier-crossing enzyme (JR-141): 26-week results from a phase 3 study in Japan suggesting significant efficacy against central nervous system and systemic symptoms | Virus Safety of Pharmaceuticals Symposium, Tokyo 2020.2.8 |
（2020.2.3） （2020.2.13） |
| Presentation | Issues in ensuring the quality and safety of allogeneic regenerative medical products | Virus Safety of Pharmaceuticals Symposium, Tokyo 2020.2.8 |
|
| Publication | Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses | International Journal of Molecular Sciences 2020, 21(2), 400 2020.1.8 |
|
| Publication | Development of therapeutics for Lysosomal Strage Disorders using a Blood-Brain Barrier penetrating technology | Official Journal of the Japan Society of Drug Delivery System Vol.34 No.5, 2019. 11 |
|
| Presentation | Cell Therapy Manufacturing: Challenges and Solutions -Challenges for manufacture of Allogeneic regenerative medicine product- |
Regenerative medicine Japan 2019, Yokohama 2019.10.10 |
| Classification | Presentation |
| Title | Advanced case report of approval for regenerative medical products |
| Presentations / Publications | 6th Global Quality Assurance Conference, Sendai 2020.2.17-20 |
| News |
| Classification | Presentation |
| Title | A novel approach to CNS dysfunction of Pompe disease with a fusion protein consisting of anti-transferrin receptor antibody and GAA enzyme |
| Presentations / Publications | 16th Annual WORLDSymposium™ 2020, Florida, USA 2020.2.10-13 |
| News | （2020.2.3） （2020.2.13） |
| Classification | Presentation |
| Title | Results from a phase 2 trial of a blood-brain barrier penetrating enzyme (JR-141) in patients with MPS II in Brazil |
| Presentations / Publications | 16th Annual WORLDSymposium™ 2020, Florida, USA 2020.2.10-13 |
| News | （2020.2.3） （2020.2.13） |
| Classification | Presentation |
| Title | Therapy for mucopolysaccharidosis II with an intravenous blood-brain barrier-crossing enzyme (JR-141): 26-week results from a phase 3 study in Japan suggesting significant efficacy against central nervous system and systemic symptoms |
| Presentations / Publications | Virus Safety of Pharmaceuticals Symposium, Tokyo 2020.2.8 |
| News | （2020.2.3） （2020.2.13） |
| Classification | Presentation |
| Title | Issues in ensuring the quality and safety of allogeneic regenerative medical products |
| Presentations / Publications | Virus Safety of Pharmaceuticals Symposium, Tokyo 2020.2.8 |
| News |
| Classification | Publication |
| Title | Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses |
| Presentations / Publications | International Journal of Molecular Sciences 2020, 21(2), 400 2020.1.8 |
| News |
| Classification | Publication |
| Title | Development of therapeutics for Lysosomal Strage Disorders using a Blood-Brain Barrier penetrating technology |
| Presentations / Publications | Official Journal of the Japan Society of Drug Delivery System Vol.34 No.5, 2019. 11 |
| News |
| Classification | Presentation |
| Title | Cell Therapy Manufacturing: Challenges and Solutions -Challenges for manufacture of Allogeneic regenerative medicine product- |
| Presentations / Publications | Regenerative medicine Japan 2019, Yokohama 2019.10.10 |
| News |
| Classification | Title | Presentations / Publications | News |
| Presentation | Targeting the Central Nervous System (CNS): ERT with BBB-penetrating Enzyme vs AAV Gene Therapy in Mouse Model of Mucopolysaccharidosis Type II |
The 5th International Forum of Lysosomal Disorders, Tokyo 2019.7.11-13 |
|
| Presentation | Novel enzyme replacement therapies for LSDs: challenges to address neurodegeneration | The 5th International Forum of Lysosomal Disorders, Tokyo 2019.7.11-13 |
|
| Presentation | 3rd Generation of electronically-controlled-injectors through the partnership between a Biopharmaceutical and an Electronics company. | Prefilled syringe Seminar 2019, Tokyo 2019.5.22 |
|
| Presentation | Establishment and characterization of the human transferrin receptor knock-in mouse | The 66th Annual Meeting of the Japanese Association for Laboratory Animal Science, Fukuoka 2019.5.15-17 |
|
| Presentation | The approach for the development of regenerative medicine in JCR pharmaceuticals -effective collaboration with Kobe Biomedical Innovation Cluster- | The 18th Congress of the Japanese Society for Regenerative Medicine , Kobe 2019.3.21-23 |
|
| Presentation | Development of therapeutics for rare diseases using a Blood-Brain Barrier penetrating technology | 139th Annual Meeting of the Pharmaceutical Society of Japan 2019.3.20-23 |
|
| Presentation | Current situatinon and issues for the development of allogeneic regenerative medicine -through the development of TEMCELL® HS Inj, the first allogeneic mesenchymal stem cell product in Japan- | FY2019 Medical Industry Innovation Forum, Tokyo 2019.3.12 |
|
| Presentation | Novel therapeutic approach for treatment of CNS manifestations in patients with Mucopolysaccharidosis | 2nd Asia Pacific Lysosomal Conference,New Zealand 2019.2.14-16 |
|
| Presentation | Non-clinical evaluation of a blood-brain barrier -penetrating enzyme for the treatment of Mucopolysaccharidosis I | 15th Annual WORLDSymposium™ 2019, Orlando, Florida 2019.2.4-8 |
（2019.1.23） （2019.2.12） |
| Publication | Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial | Molecular Therapy Volume 27, Issue 2, 6 February 2019, Pages 456-464 |
| Classification | Presentation |
| Title | Targeting the Central Nervous System (CNS): ERT with BBB-penetrating Enzyme vs AAV Gene Therapy in Mouse Model of Mucopolysaccharidosis Type II |
| Presentations / Publications | The 5th International Forum of Lysosomal Disorders, Tokyo 2019.7.11-13 |
| News |
| Classification | Presentation |
| Title | Novel enzyme replacement therapies for LSDs: challenges to address neurodegeneration |
| Presentations / Publications | The 5th International Forum of Lysosomal Disorders, Tokyo 2019.7.11-13 |
| News |
| Classification | Presentation |
| Title | 3rd Generation of electronically-controlled-injectors through the partnership between a Biopharmaceutical and an Electronics company. |
| Presentations / Publications | Prefilled syringe Seminar 2019, Tokyo 2019.5.22 |
| News |
| Classification | Presentation |
| Title | Establishment and characterization of the human transferrin receptor knock-in mouse |
| Presentations / Publications | The 66th Annual Meeting of the Japanese Association for Laboratory Animal Science, Fukuoka 2019.5.15-17 |
| News |
| Classification | Presentation |
| Title | The approach for the development of regenerative medicine in JCR pharmaceuticals -effective collaboration with Kobe Biomedical Innovation Cluster- |
| Presentations / Publications | The 18th Congress of the Japanese Society for Regenerative Medicine , Kobe 2019.3.21-23 |
| News |
| Classification | Presentation |
| Title | Development of therapeutics for rare diseases using a Blood-Brain Barrier penetrating technology |
| Presentations / Publications | 139th Annual Meeting of the Pharmaceutical Society of Japan 2019.3.20-23 |
| News |
| Classification | Presentation |
| Title | Current situatinon and issues for the development of allogeneic regenerative medicine -through the development of TEMCELL® HS Inj, the first allogeneic mesenchymal stem cell product in Japan- |
| Presentations / Publications | FY2019 Medical Industry Innovation Forum, Tokyo 2019.3.12 |
| News |
| Classification | Presentation |
| Title | Novel therapeutic approach for treatment of CNS manifestations in patients with Mucopolysaccharidosis |
| Presentations / Publications | 2nd Asia Pacific Lysosomal Conference,New Zealand 2019.2.14-16 |
| News |
| Classification | Presentation |
| Title | Non-clinical evaluation of a blood-brain barrier -penetrating enzyme for the treatment of Mucopolysaccharidosis I |
| Presentations / Publications | 15th Annual WORLDSymposium™ 2019, Orlando, Florida 2019.2.4-8 |
| News | （2019.1.23） （2019.2.12） |
| Classification | Publication |
| Title | Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial |
| Presentations / Publications | Molecular Therapy Volume 27, Issue 2, 6 February 2019, Pages 456-464 |
| News | （2018.12.21） |